Alto Neuroscience Files 8-K

Ticker: ANRO · Form: 8-K · Filed: 2025-02-12T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, disclosure

TL;DR

Alto Neuro filed an 8-K, standard stuff, no major news yet.

AI Summary

Alto Neuroscience, Inc. filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing does not contain specific financial figures or details about the 'Other Events' beyond its classification.

Why It Matters

This 8-K filing indicates a standard corporate disclosure event for Alto Neuroscience, Inc., but lacks specific operational or financial details that would immediately impact investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K with no specific negative or positive events detailed, indicating low immediate risk.

Key Players & Entities

Alto Neuroscience, Inc. (company) — Registrant
February 12, 2025 (date) — Date of earliest event reported

FAQ

What specific 'Other Events' are being reported by Alto Neuroscience, Inc. in this 8-K filing?

The filing categorizes the event as 'Other Events' but does not provide specific details about the nature of these events within the provided text.

When was this 8-K filing submitted to the SEC?

The filing was submitted on February 12, 2025.

What is Alto Neuroscience, Inc.'s principal executive office address?

The address is 650 Castro Street, Suite 450, Mountain View, CA 94041.

What is the Commission File Number for Alto Neuroscience, Inc.?

The Commission File Number is 001-41944.

What is the IRS Employer Identification Number for Alto Neuroscience, Inc.?

The IRS Employer Identification Number is 83-4210124.

From the Filing

0001193125-25-024814.txt : 20250212 0001193125-25-024814.hdr.sgml : 20250212 20250212081630 ACCESSION NUMBER: 0001193125-25-024814 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250212 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250212 DATE AS OF CHANGE: 20250212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 25612106 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 8-K 1 d876505d8k.htm 8-K 8-K false 0001999480 0001999480 2025-02-12 2025-02-12     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2025     ALTO NEUROSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter)       Delaware   001-41944   83-4210124 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   650 Castro Street , Suite 450 , Mountain View , CA   94041 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (650) 200-0412 N/A (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.0001 par value per share   ANRO   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 8.01 Other Events. On February 12, 2025, Alto Neuroscience, Inc. issued a press release entitled “Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.   Item 9.01 Financial Statements and Exhibits. (d) Exhibits.   Exhibit No.    Description 99.1    Press Release of Alto Neuroscience, Inc. 104    Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursu